Johannes A Veit1, Daniela Heine1, Julia Thierauf1, Jochen Lennerz2, Subasch Shetty3, Patrick J Schuler1, Theresa Whiteside4, Dirk Beutner5, Moritz Meyer5, Inga Grünewald6, Gerd Ritter7, Sacha Gnjatic8, Andrew G Sikora9, Thomas K Hoffmann1, Simon Laban1. 1. Department of Oto-Rhino-Laryngology and Head and Neck Surgery, University Medical Center Ulm, Ulm, Germany. 2. Department of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital, Boston, Massachusetts. 3. Department of Ear, Nose and Throat Surgery, Kensington Hospital, Whangarei, New Zealand. 4. Department of Pathology, University of Pittsburgh, Hillman Cancer Center, Pittsburgh, Pennsylvania. 5. Department of Otorhinolaryngology, University of Cologne, Cologne, Germany. 6. Institute of Pathology, University of Cologne, Cologne, Germany. 7. Ludwig Institute for Cancer Research and Memorial Sloan Kettering Cancer Center, New York, New York. 8. Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, New York. 9. Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas.
Abstract
BACKGROUND: Adenoid cystic carcinoma (ACC) of the head and neck is a rare but highly malignant tumor. Cancer-testis antigens (CTAs) represent an immunogenic family of cancer-specific proteins and thus represent an attractive target for immunotherapy. METHODS: Eighty-four cases of ACC were identified, the CTAs pan-Melanoma antigen (pan-MAGE; M3H67) and New York esophageal squamous cell carcinoma (NY-ESO-1; E978) were detected immunohistochemically (IHC) and correlated with clinical data. RESULTS: Expression of NY-ESO-1 was found in 48 of 84 patients (57.1%) and of pan-MAGE in 28 of 84 patients (31.2%). Median overall survival (OS) in NY-ESO-1 positive versus negative patients was 130.8 and 282.0 months (p = .223), respectively. OS in pan-MAGE positive versus negative patients was 105.3 and 190.5 months, respectively (p = .096). Patients expressing both NY-ESO-1 and pan-MAGE simultaneously had significantly reduced OS with a median of 90.5 months compared with 282.0 months in negative patients (p = .047). CONCLUSION: A significant fraction of patients with ACC show expression of the CTAs NY-ESO-1 and/or pan-MAGE with promising immunotherapeutic implications.
BACKGROUND:Adenoid cystic carcinoma (ACC) of the head and neck is a rare but highly malignant tumor. Cancer-testis antigens (CTAs) represent an immunogenic family of cancer-specific proteins and thus represent an attractive target for immunotherapy. METHODS: Eighty-four cases of ACC were identified, the CTAs pan-Melanoma antigen (pan-MAGE; M3H67) and New York esophageal squamous cell carcinoma (NY-ESO-1; E978) were detected immunohistochemically (IHC) and correlated with clinical data. RESULTS: Expression of NY-ESO-1 was found in 48 of 84 patients (57.1%) and of pan-MAGE in 28 of 84 patients (31.2%). Median overall survival (OS) in NY-ESO-1 positive versus negative patients was 130.8 and 282.0 months (p = .223), respectively. OS in pan-MAGE positive versus negative patients was 105.3 and 190.5 months, respectively (p = .096). Patients expressing both NY-ESO-1 and pan-MAGE simultaneously had significantly reduced OS with a median of 90.5 months compared with 282.0 months in negative patients (p = .047). CONCLUSION: A significant fraction of patients with ACC show expression of the CTAs NY-ESO-1 and/or pan-MAGE with promising immunotherapeutic implications.
Keywords:
Melanoma antigen; New York esophageal squamous cell carcinoma (NY-ESO-1); adenoid cystic carcinoma; cancer-testis antigens; head and neck cancer
Authors: Geoffrey T Gibney; Ragini R Kudchadkar; Ronald C DeConti; Melissa S Thebeau; Maria P Czupryn; Leticia Tetteh; Cabell Eysmans; Allison Richards; Michael J Schell; Kate J Fisher; Christine E Horak; H David Inzunza; Bin Yu; Alberto J Martinez; Ibrahim Younos; Jeffrey S Weber Journal: Clin Cancer Res Date: 2014-12-18 Impact factor: 12.531
Authors: David L A Figueiredo; Rui C M Mamede; Giulio C Spagnoli; Wilson A Silva; Marco Zago; Luciano Neder; Achim A Jungbluth; Fabiano P Saggioro Journal: Head Neck Date: 2010-09-30 Impact factor: 3.147
Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Sylvia Adams; David W O'Neill; Daisuke Nonaka; Elizabeth Hardin; Luis Chiriboga; Kimberly Siu; Crystal M Cruz; Angelica Angiulli; Francesca Angiulli; Erika Ritter; Rose Marie Holman; Richard L Shapiro; Russell S Berman; Natalie Berner; Yongzhao Shao; Olivier Manches; Linda Pan; Ralph R Venhaus; Eric W Hoffman; Achim Jungbluth; Sacha Gnjatic; Lloyd Old; Anna C Pavlick; Nina Bhardwaj Journal: J Immunol Date: 2008-07-01 Impact factor: 5.422
Authors: Niels Halama; Sara Michel; Matthias Kloor; Inka Zoernig; Thora Pommerencke; Magnus von Knebel Doeberitz; Peter Schirmacher; Jürgen Weitz; Niels Grabe; Dirk Jäger Journal: Cancer Immun Date: 2009-02-19
Authors: Cecilia Nordfors; Nathalie Grün; Nikolaos Tertipis; Andreas Ährlund-Richter; Linnea Haeggblom; Lars Sivars; Juan Du; Tommy Nyberg; Linda Marklund; Eva Munck-Wikland; Anders Näsman; Torbjörn Ramqvist; Tina Dalianis Journal: Eur J Cancer Date: 2013-04-06 Impact factor: 9.162
Authors: Simon Laban; Gregor Giebel; Niklas Klümper; Andreas Schröck; Johannes Doescher; Giulio Spagnoli; Julia Thierauf; Marie-Nicole Theodoraki; Romain Remark; Sacha Gnjatic; Rosemarie Krupar; Andrew G Sikora; Geert Litjens; Niels Grabe; Glen Kristiansen; Friedrich Bootz; Patrick J Schuler; Cornelia Brunner; Johannes Brägelmann; Thomas K Hoffmann; Sven Perner Journal: Oncotarget Date: 2017-02-28